Bambusa Therapeutics closed Seed round

Bambusa Therapeutics Inc. closed its Series Seed financing round, raising approximately $15 million. The financing was co-led by BVF Partners L.P. and Dawn Biopharma, a platform controlled by KKR, with participation from Salvia GmbH and INCE Capital.

Bambusa Therapeutics is a biotechnology company focused on developing bispecific antibodies for the treatment of immunological and inflammatory (I&I) disorders. The company intends to use the funds to accelerate the development of its pipeline of bispecific antibodies to Phase I clinical studies. Bambusa leverages validated targets to create bispecific antibody therapeutics through innovative antibody engineering, aiming to achieve best-in-disease profiles for multiple indications. Two of the company's four programs are on track to enter the clinic in 2025.